{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:34:02Z","timestamp":1790105642064,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["759161"],"award-info":[{"award-number":["759161"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.metabol.2022.155396","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T11:36:53Z","timestamp":1672400213000},"page":"155396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5846-4444","authenticated-orcid":false,"given":"Anna","family":"Veelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-1979","authenticated-orcid":false,"given":"Charlotte","family":"Andriessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvo","family":"Op den Kamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0106-1169","authenticated-orcid":false,"given":"Edmundo","family":"Erazo-Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9209-7230","authenticated-orcid":false,"given":"Marlies","family":"de Ligt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Mevenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna A.","family":"J\u00f6rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Moonen-Kornips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4259-9528","authenticated-orcid":false,"given":"Gert","family":"Schaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Esterline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Havekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4573-517X","authenticated-orcid":false,"given":"Jan","family":"Oscarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7795-584X","authenticated-orcid":false,"given":"Vera B.","family":"Schrauwen-Hinderling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2672-0415","authenticated-orcid":false,"given":"Esther","family":"Phielix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-847X","authenticated-orcid":false,"given":"Patrick","family":"Schrauwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.metabol.2022.155396_bb0005","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2022.155396_bb0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.metabol.2022.155396_bb0015","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.metabol.2022.155396_bb0020","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.metabol.2022.155396_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009417","article-title":"SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","volume":"6","author":"Shyangdan","year":"2016","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.metabol.2022.155396_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose Cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"10.1016\/j.metabol.2022.155396_bb0035","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1080\/14656566.2020.1795132","article-title":"Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile","volume":"21","author":"Muzurovi\u0107","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"10.1016\/j.metabol.2022.155396_bb0040","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155396_bb0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13098-020-00545-z","article-title":"The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease","volume":"12","author":"Ohara","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.metabol.2022.155396_bb0050","doi-asserted-by":"crossref","DOI":"10.2337\/dc20-2887","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2 diabetes: a randomized, double-blind crossover trial","author":"Op den Kamp","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.metabol.2022.155396_bb0055","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.metabol.2022.155396_bb0060","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.metabol.2022.155396_bb0065","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.metabol.2022.155396_bb0070","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jdi.12370","article-title":"Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: a study using continuous glucose monitoring","volume":"6","author":"Yamada","year":"2015","journal-title":"JDiabetes Investig"},{"issue":"5","key":"10.1016\/j.metabol.2022.155396_bb0075","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.metabol.2022.155396_bb0080","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.metabol.2022.155396_bb0085","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4,placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.metabol.2022.155396_bb0090","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.metabol.2022.155396_bb0095","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00125-015-3845-8","article-title":"Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes","volume":"59","author":"Muscelli","year":"2016","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.metabol.2022.155396_bb0100","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/ncomms3316","article-title":"Glycogen shortage during fasting triggers liver\u2013brain\u2013adipose neurocircuitry to facilitate fat utilization","volume":"4","author":"Izumida","year":"2013","journal-title":"Nat Commun"},{"issue":"3 Pt 1","key":"10.1016\/j.metabol.2022.155396_bb0105","first-page":"E623","article-title":"Role of glycogen-lowering exercise in the change of fat oxidation in response to a high-fat diet","volume":"273","author":"Schrauwen","year":"1997","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.metabol.2022.155396_bb0110","first-page":"E1130","article-title":"Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss","volume":"277","author":"Kelley","year":"1999","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.metabol.2022.155396_bb0115","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/oby.2008.24","article-title":"Impaired skeletal muscle substrate oxidation in glucose-intolerant men improves after weight loss","volume":"16","author":"Corpeleijn","year":"2008","journal-title":"Obesity"},{"issue":"6","key":"10.1016\/j.metabol.2022.155396_bb0120","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/BF02850219","article-title":"The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease","volume":"23","author":"Sit","year":"2006","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.metabol.2022.155396_bb0125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0735-1097(97)00185-X","article-title":"Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure","volume":"30","author":"Swan","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.metabol.2022.155396_bb0130","first-page":"2191","volume":"310","year":"2013"},{"issue":"3","key":"10.1016\/j.metabol.2022.155396_bb0135","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2337\/diacare.24.3.539","article-title":"A model-based method for assessing insulin sensitivity from the oral glucose tolerance test","volume":"24","author":"Mari","year":"2001","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.metabol.2022.155396_bb0140","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1152\/jappl.1997.83.6.2064","article-title":"A dual-respiration chamber system with automated calibration","volume":"83","author":"Schoffelen","year":"1997","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.metabol.2022.155396_bb0145","first-page":"32","article-title":"The reliability and validity of the macronutrient and taste preference ranking task: a new method to measure food preferences","volume":"57","author":"de Bruijn","year":"2017","journal-title":"Food QualPreference"},{"issue":"7","key":"10.1016\/j.metabol.2022.155396_bb0150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3109\/00365517509095787","article-title":"Percutaneous needle biopsy of skeletal muscle in physiological and clinical research","volume":"35","author":"Bergstrom","year":"1975","journal-title":"Scand J Clin Lab Invest"},{"issue":"1","key":"10.1016\/j.metabol.2022.155396_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1472-6823-13-47","article-title":"Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study","volume":"13","author":"Gayoso-Diz","year":"2013","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.metabol.2022.155396_bb0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0092-8674(00)80611-X","article-title":"Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1","volume":"98","author":"Wu","year":"1999","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.metabol.2022.155396_bb0165","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2337\/dc20-1983","article-title":"Gluconeogenesis, but not glycogenolysis, contributes to the increase in endogenous glucose production by SGLT-2 inhibition","volume":"44","author":"Wolf","year":"2021","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.metabol.2022.155396_bb0170","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1042\/CS20140681","article-title":"Diurnal variation in skeletal muscle and liver glycogen in humans with normal health and Type 2 diabetes","volume":"128","author":"Macauley","year":"2015","journal-title":"Clin Sci"},{"issue":"3","key":"10.1016\/j.metabol.2022.155396_bb0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11892-008-0030-1","article-title":"Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus","volume":"8","author":"Abdul-Ghani","year":"2008","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.metabol.2022.155396_bb0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.metabol.2022.155396_bb0185","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/21623945.2020.1807850","article-title":"The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1\u03b1 signalling pathway","volume":"9","author":"Yang","year":"2020","journal-title":"Adipocyte"},{"key":"10.1016\/j.metabol.2022.155396_bb0190","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol"},{"issue":"3","key":"10.1016\/j.metabol.2022.155396_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040076","article-title":"Calorie restriction increases muscle mitochondrial biogenesis in healthy humans","volume":"4","author":"Civitarese","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.metabol.2022.155396_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101050","article-title":"Day-night rhythm of skeletal muscle metabolism is disturbed in older, metabolically compromised individuals","volume":"41","author":"Wefers","year":"2020","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2022.155396_bb0205","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/dia.2019.0372","article-title":"Canagliflozin increases calorie intake in type 2 diabetes without changing the energy ratio of the three macronutrients: CANA-K study","volume":"22","author":"Matsuba","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.metabol.2022.155396_bb0210","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.diabres.2017.11.016","article-title":"Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment","volume":"135","author":"Horie","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.metabol.2022.155396_bb0215","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nm.3891","article-title":"Short-term cold acclimation improves insulin sensitivity in patients with type 2 diabetes mellitus","volume":"21","author":"Hanssen","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.metabol.2022.155396_bb0220","first-page":"E165","article-title":"Exercise training reduces intrahepatic lipid content in people with and people without nonalcoholic fatty liver","volume":"314","author":"Brouwers","year":"2017","journal-title":"AmJPhysiolEndocrinolMetab"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522002748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522002748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:33:16Z","timestamp":1758429196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049522002748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"alternative-id":["S0026049522002748"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155396","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"155396"}}